MX2018011306A - Vector multimodal para infeccion de celulas dentriticas. - Google Patents

Vector multimodal para infeccion de celulas dentriticas.

Info

Publication number
MX2018011306A
MX2018011306A MX2018011306A MX2018011306A MX2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A MX 2018011306 A MX2018011306 A MX 2018011306A
Authority
MX
Mexico
Prior art keywords
cell
dendritic cell
cancer
cell infection
viral nucleic
Prior art date
Application number
MX2018011306A
Other languages
English (en)
Inventor
Soon-Shiong Patrick
Niazi Kayvan
Rabizadeh Shahrooz
Original Assignee
Nantcell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantcell Inc filed Critical Nantcell Inc
Publication of MX2018011306A publication Critical patent/MX2018011306A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)

Abstract

Los virus recombinantes y acidos nucleicos virales se contemplan que proporcionan a la celula infectada varias moleculas reguladoras que estimulan la actividad de la celula T y celula NK y que suprime la inhibicion de la actividad de la celula T y celula NK. Mas preferiblemente, el virus y acido nucleico viral incluira ademas una secuencia asociada al cancer humano, y especialmente una secuencia que codifica una pluralidad de antigenos asociados al cancer, antigenos especificos al cancer, y/o neoantigenos especificos al tumor o al paciente. Especialmente las moléculas reguladoras especificas incluyen CD80 (B7.1), CD86 (B7.2), CD54 (ICAM-1/BB2), CD11 (LFA-1), y un inhibidor de CTLA-4.
MX2018011306A 2016-03-18 2017-03-20 Vector multimodal para infeccion de celulas dentriticas. MX2018011306A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662310551P 2016-03-18 2016-03-18
US201662313596P 2016-03-25 2016-03-25
PCT/US2017/023117 WO2017161360A2 (en) 2016-03-18 2017-03-20 Multimodal vector for dendritic cell infection

Publications (1)

Publication Number Publication Date
MX2018011306A true MX2018011306A (es) 2019-08-16

Family

ID=59850551

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011306A MX2018011306A (es) 2016-03-18 2017-03-20 Vector multimodal para infeccion de celulas dentriticas.

Country Status (11)

Country Link
US (1) US20210198689A1 (es)
EP (1) EP3430148A4 (es)
JP (1) JP2019508044A (es)
KR (1) KR20180118198A (es)
CN (1) CN109312364A (es)
AU (1) AU2017233072B2 (es)
CA (1) CA3016389A1 (es)
IL (1) IL261812A (es)
MX (1) MX2018011306A (es)
SG (1) SG11201808058PA (es)
WO (1) WO2017161360A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201414021D0 (en) 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
MX2017013684A (es) 2015-04-30 2018-08-28 Psioxus Therapeutics Ltd Adenovirus oncolitico que codifica una proteina b7.
CN108351917B (zh) 2015-08-25 2022-03-08 南托米克斯有限责任公司 用于高精度识别变体的系统和方法
CA3006859A1 (en) 2015-12-17 2017-06-22 Psioxus Therapeutics Limited Group b adenovirus encoding an anti-tcr-complex antibody or fragment
KR20190031492A (ko) 2016-06-30 2019-03-26 난트 홀딩스 아이피, 엘엘씨 난트 암 백신(nant cancer vaccine)
CN109862912B (zh) 2016-08-29 2024-08-02 阿卡米斯生物公司 携带双特异性t细胞衔接器的腺病毒
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CN111246867B (zh) 2017-06-01 2024-04-12 阿卡米斯生物公司 溶瘤病毒和方法
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
US11823773B2 (en) 2018-04-13 2023-11-21 Nant Holdings Ip, Llc Nant cancer vaccine strategies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2678259C (en) * 1998-12-09 2016-10-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
ES2404689T3 (es) * 2001-04-05 2013-05-28 The Johns Hopkins University Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2
WO2003039591A2 (de) * 2001-11-09 2003-05-15 Medigene Aktiengesellschaft Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
CN1761757A (zh) * 2003-01-07 2006-04-19 香港大学 用血管抑制素协同加强腺伴随病毒介导的b7.1免疫接种以根除扩散的肝转移性肿瘤
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
US20080248067A1 (en) * 2005-04-14 2008-10-09 The University Of Queensland Immunomodulating Compositions and Uses Therefor
WO2012038606A1 (en) * 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
PL2751279T3 (pl) * 2011-08-31 2018-03-30 St. Jude Children's Research Hospital Sposoby i kompozycje do wykrywania poziomu aktywności lizosomalnej egzocytozy i sposoby zastosowania
CN102533859A (zh) * 2012-01-12 2012-07-04 中国人民解放军第二军医大学 携带可诱导性共刺激分子基因的腺病毒载体及其构建方法与应用
CN109134640A (zh) * 2012-10-23 2019-01-04 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
ES2715890T3 (es) * 2013-11-01 2019-06-06 Pfizer Vectores de expresión de antígenos asociados a la próstata
KR20160070095A (ko) * 2013-11-05 2016-06-17 버베리안 노딕 에이/에스 종양 항원을 발현하는 폭스바이러스 및 면역 관문 저해제의 길항제 및/또는 효현제를 구비하는 암을 치료하기 위한 복합제 치료제
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
ES2963718T3 (es) * 2014-01-21 2024-04-01 Novartis Ag Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
GB201406608D0 (en) * 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
IL248507B (en) * 2014-05-13 2022-07-01 Bavarian Nordic As Combined therapy for the treatment of cancer with a recombinant focovirus that expresses an antigen and an antagonist or agonist for an immune control molecule

Also Published As

Publication number Publication date
KR20180118198A (ko) 2018-10-30
AU2017233072A1 (en) 2018-09-13
WO2017161360A3 (en) 2017-10-26
SG11201808058PA (en) 2018-10-30
JP2019508044A (ja) 2019-03-28
EP3430148A2 (en) 2019-01-23
AU2017233072B2 (en) 2020-12-24
CN109312364A (zh) 2019-02-05
US20210198689A1 (en) 2021-07-01
CA3016389A1 (en) 2017-09-21
IL261812A (en) 2018-10-31
EP3430148A4 (en) 2020-01-01
WO2017161360A4 (en) 2017-11-16
WO2017161360A2 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
MX2018011306A (es) Vector multimodal para infeccion de celulas dentriticas.
GB2573664A (en) Viral methods of T cell therapy
PH12019501130A1 (en) Viral delivery of neoantigens
CY1122571T1 (el) Μακροκυκλικοι αναστολεις των αλληλεπιδρασεων πρωτεϊνων/πρωτεϊνων ρd-1/ρd-l1 και cd80(β7-1)/ρd-l1
EP4219696A3 (en) Oncolytic virus strain
AU2016262093A8 (en) Enhancing endonuclease based gene editing in primary cells
EP4197551A3 (en) Adoptive cell transfer and oncolytic virus combination therapy
WO2017069958A3 (en) Modulation of novel immune checkpoint targets
PH12017500441A1 (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
PH12018500855A1 (en) Herpes simplex virus vaccine
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
EA201790534A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для генной терапии
MX2017010129A (es) Inmunomoduladores.
MX2019004215A (es) Insercion de genes dirigida para terapia de celulas inmunes mejorada.
WO2016073955A3 (en) Cells lacking b2m surface expression and methods for allogeneic administration of such cells
MX2017007677A (es) Inmunomoduladores.
MX2017004542A (es) Inmunomoduladores.
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
EA201790167A1 (ru) Цитомегаловирус человека, содержащий экзогенные антигены
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
EA202090700A1 (ru) Компетентные по репликации аденовирусные векторы
MX2018006373A (es) Produccion de virus en cultivos celulares.
MX2019015194A (es) Composiciones y métodos para terapia de cáncer con virus de dengue y células dendríticas.